Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical College, 233004, Bengbu, Anhui, People's Republic of China.
Anhui Key Laboratory of Tissue Transplantation, The First Affiliated Hospital of Bengbu Medical College, 287 Chang Huai Road, Bengbu, 233004, Anhui, People's Republic of China.
J Neuroinflammation. 2020 Aug 29;17(1):255. doi: 10.1186/s12974-020-01937-8.
After spinal cord injury (SCI), destructive immune cell subsets are dominant in the local microenvironment, which are the important mechanism of injury. Studies have shown that inflammasomes play an important role in the inflammation following SCI, and apoptosis-associated speck-like protein containing a card (ASC) is the adaptor protein shared by inflammasomes. Therefore, we speculated that inhibiting ASC may improve the local microenvironment of injured spinal cord. Here, CRID3, a blocker of ASC oligomerization, was used to study its effect on the local microenvironment and the possible role in neuroprotection following SCI.
Murine SCI model was created using an Infinite Horizon impactor at T9 vertebral level with a force of 50 kdynes and CRID3 (50 mg/kg) was intraperitoneally injected following injury. ASC and its downstream molecules in inflammasome signaling pathway were measured by western blot. The immune cell subsets were detected by immunohistofluorescence (IHF) and flow cytometry (FCM). The spinal cord fibrosis area, neuron survival, myelin preservation, and functional recovery were assessed.
Following SCI, CRID3 administration inhibited inflammasome-related ASC and caspase-1, IL-1β, and IL-18 activation, which consequently suppressed M1 microglia, Th1 and Th1Th17 differentiation, and increased M2 microglia and Th2 differentiation. Accordingly, the improved histology and behavior have also been found.
CRID3 may ameliorate murine SCI by inhibiting inflammasome activation, reducing proinflammatory factor production, restoring immune cell subset balance, and improving local immune microenvironment, and early administration may be a promising therapeutic strategy for SCI.
脊髓损伤(SCI)后,局部微环境中存在占主导地位的破坏型免疫细胞亚群,这是损伤的重要机制。研究表明,炎性小体在 SCI 后的炎症中发挥重要作用,而 ASC(apoptosis-associated speck-like protein containing a card)是炎性小体的衔接蛋白。因此,我们推测抑制 ASC 可能改善损伤脊髓的局部微环境。本研究采用 ASC 寡聚化阻断剂 CRID3 研究其对损伤脊髓局部微环境的影响及其在 SCI 后神经保护中的可能作用。
采用 Infinite Horizon 撞击器在 T9 椎体水平造成 50 kdynes 的力致 SCI 模型,损伤后腹腔内注射 CRID3(50mg/kg)。采用 Western blot 检测炎性小体信号通路中 ASC 及其下游分子。免疫荧光(IHF)和流式细胞术(FCM)检测免疫细胞亚群。评估脊髓纤维化面积、神经元存活、髓鞘保存和功能恢复。
SCI 后,CRID3 给药抑制了与 ASC 相关的炎性小体及其下游的 caspase-1、IL-1β 和 IL-18 的激活,从而抑制了 M1 小胶质细胞、Th1 和 Th1/Th17 的分化,并增加了 M2 小胶质细胞和 Th2 的分化。相应地,组织学和行为也得到了改善。
CRID3 通过抑制炎性小体的激活、减少促炎因子的产生、恢复免疫细胞亚群的平衡、改善局部免疫微环境,可能改善 SCI 模型,早期给药可能是 SCI 的一种有前途的治疗策略。